MINI FUTURE LONG - ELI LILLY & CO | Delayed Deutsche Boerse AG 06:50:13 02/07/2024 pm IST | ||
| 63.29 EUR | -2.21% |
|
| Current month | +0.65% | ||
| 1 month | +17.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 02/24/02 | 63.29 | -2.21% |
| 01/24/01 | 64.72 | +0.65% |
| 28/24/28 | 64.3 | +0.27% |
| 27/24/27 | 64.13 | +0.58% |
| 26/24/26 | 63.76 | +0.11% |
Delayed Quote Deutsche Boerse AG
Last update July 02, 2024 at 06:50 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PH21VM |
| ISIN | DE000PH21VM5 |
| Date issued | 30/06/2021 |
| Strike | 220.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.05 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 65 € |
|---|---|
| Lowest since issue | 3.3 € |
| Spread | 0.15 € |
| Spread % | 0.24% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
- Stock Market
- Certificates
- Certificat
